Toripalimab Combined With Beat Chemotherapy in the Treatment of Advanced Back-line Small Cell Lung Cancer

Starting soon · Phase 2

Conditions studied: SCLC, Extensive Stage, Bayesian, Metronomic Chemotherapy

In brief

This study is a randomized, open-label, multi-center investigator-initiated clinical trial. Patients who meet the inclusion criteria receive the treatment plan stipulated in the protocol. A Bayesian design is used to explore the efficacy and safety of teprotumumab combined with pulse chemotherapy in the treatment of advanced second-line extensive-stage small cell lung cancer.

Key facts

Study ID

NCT07698054

Run by

Henan Cancer Hospital

People needed

130

Starts

2026-08-01

Expected to finish

2030-12-31

Last updated by the study team

2026-07-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 1.Age ≥18 years old, both male and female are acceptable.
• 2. Histology and pathology diagnosis of extensive stage small cell lung cancer, and must meet the following standards:
• always has not received the immune therapy,
• Previously received immunotherapy, with the number of treatment lines ≥2 and the immunotherapy being effective(immunotherapy PFS > 3 months, withdrawal time > 3 months)
• never used anlotinib,
• 3. ECOG: 0 \~ 2;
• 4 . The expected lifetime 12 weeks or more;
• 5. Major organs function normal

You may not qualify if…

• 1.Those who are allergic to toripalimab or etoposide or have metabolic disorders;
• 2.With known the special ripley sheet resistance, etoposide contraindication;
• 3.Other circumstances that the researcher assessed as unsuitable for participation in this clinical study.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.